Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry
radiation directly to cancer cells and not harm normal cells. Bortezomib may stop the growth
of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood
flow to the cancer. Bortezomib may also make cancer cells more sensitive to radiation
therapy. Giving samarium Sm 153 lexidronam pentasodium together with bortezomib may kill more
cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of bortezomib when
given together with samarium Sm 153 lexidronam pentasodium and to see how well they work in
treating patients with relapsed or refractory multiple myeloma.